Pedro Such, MD

Good, moderate, and poor functioning of adult patients with schizophrenia treated with aripiprazole once-monthly or paliperidone palmitate once-monthly in the Qualify study

Introduction QUALIFY was a 28-week, randomized, open-label, rater-blinded, head-to-head study (NCT01795547) evaluating effectiveness of aripiprazole once-monthly (AOM 400) vs paliperidone...

Simon Nitschky Schmidt , PhD;

Lizbeth Arias , MD;

Ross Baker , PhD, MBA;

Pedro Such , MD;

Jessica Madera , MD;

10/08/2020

Functioning in de novo and rollover patients with bipolar I disorder receiving aripiprazole once-monthly in a 52-week, open-label study

Objectives: Aripiprazole once-monthly 400 mg (AOM 400) is a long-acting injectable formulation of aripiprazole licensed in the US, Canada and Australia for maintenance treatment of adults...

Maxine Chen , PhD;

Ross Baker , PhD, MBA;

Pedro Such , MD;

Cathy Zhao , PhD;

Jessica Madera , MD;

10/08/2020

Analysis of Sexual Function in a Study With Aripiprazole Once-Monthly Versus Paliperidone Palmitate Once-Monthly

Introduction: Sexual dysfunction is a common side effect of antipsychotic treatment and may contribute to non-adherence. In the QUALIFY study (NCT01795547) the effectiveness of aripiprazo...

Pedro Such , MD;

Jessica Madera , MD;

Ross Baker , PhD, MBA;

Heather Fitzgerald ;

Louise Rosenberg Christ , PhD;

11/22/2019

Effects of Aripiprazole Once-Monthly and Paliperidone Palmitate Once Monthly in Patients With Schizophrenia and Concomitant Substance Use: A Post-hoc Analysis of QUALIFY, a Head-to-Head Study

Background: Post-hoc analyses of the QUALIFY study (1), comparing effects of aripiprazole once-monthly (AOM 400) and paliperidone palmitate once-monthly (PP1M) treatment in patients with ...

Ross Baker , PhD, MBA;

Pedro Such , MD;

Jessica Madera , MD;

Simon Nitschky Schmidt , PhD;

Anna-Greta Nylander , PhD;

11/22/2019

The Efficacy and Safety of Aripiprazole Once-Monthly 400mg (AOM 400) in African American/Black Patients Compared to Non-African American/Black Patients

Background: Recent analyses have indicated that medical treatment for schizophrenia varies among racial groups.

Jessica Madera , MD;

Stephen Murray , PharmD, MBA;

Maxine Chen , PhD;

Ross Baker , PhD, MBA;

Pedro Such , MD;

Cathy Zhao , PhD;

11/22/2019

Efficacy and Safety of Aripiprazole Once-monthly in Patients With Relatively Rapid and Non-Rapid Cycling Bipolar I Disorder

Objective: To assess the efficacy and safety of Aripiprazole Once-Monthly (AOM 400) in preventing recurrence of mood episodes in patients with rapid and non-rapid cycling Bipolar I disord...

Ross Baker , PhD, MBA;

Maninder Malik , PhD;

Pedro Such , MD;

Cathy Zhao , PhD;

Jessica Madera , MD;

03/01/2019

Effects of Aripiprazole Once-monthly (AOM) Across Manic Symptoms in Patients with Bipolar I Disorder (BP-I)

Background: The established role of oral aripiprazole in the treatment of Bipolar I disorder (BP-I) and the potential for a long-acting injectable formulation to improve adherence and pre...

Ross Baker , PhD, MBA;

Maninder Malik , PhD;

Pedro Such , MD;

Cathy Zhao , PhD;

Jessica Madera , MD;

03/01/2019

Characteristics of Patients in Recovery Versus Patients With Recurrence in a Randomized Placebo-Controlled Study With Aripiprazole Once-Monthly as Maintenance Treatment for Bipolar I Disorder

Aims. To describe the background and clinical characteristics of patients who did versus those who did not have a recurrence of a mood episode during up to 52 weeks of maintenance treatme...

Peter Zhang , PhD;

Ross Baker , PhD, MBA;

Pedro Such , MD;

Jessica Madera , MD;

Mauricio Tohen , MD, DrPH, MBA;

03/01/2019

Assessment of Functional Recovery After Long-term Aripiprazole Once-Monthly Maintenance Treatment of Bipolar I Disorder

Background: Functional assessment is complex and often overlooked in patients with bipolar I disorder. The Functioning Assessment Short Test (FAST) assesses optimal functioning in these p...

Peter Zhang , PhD;

Ross Baker , PhD, MBA;

Thomas Brown , PhD;

Mauricio Tohen , MD, DrPH, MBA;

Pedro Such , MD;

Jessica Madera , MD;

Craig Surman , MD;

03/01/2019

Safety And Tolerability of Multiple-Dose Aripiprazole 2-Month Ready-to-Use 960 mg Versus Aripiprazole Once-Monthly 400 mg in Adults With Schizophrenia or Bipolar I Disorder

Abstract: Background: Aripiprazole 2-month ready-to-use 960 mg (2MRTU 960) is a new long-acting injectable (LAI) antipsychotic formulation for gluteal administration every 2 months, inten...

Pedro Such , MD;

Sarah Ramsden ;

01/19/2023